6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 30 Oct 2025
- Reporting date
- 30 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,820 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 276-300 of 1,000 matching filings.
Per page
25
Current page
12
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 29 Oct 2025
- Reporting date
- 29 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
3RD QUARTER RESULTS
- Filing date
- 29 Oct 2025
- Reporting date
- 29 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 28 Oct 2025
- Reporting date
- 28 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU
- Filing date
- 28 Oct 2025
- Reporting date
- 28 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 27 Oct 2025
- Reporting date
- 27 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA
- Filing date
- 24 Oct 2025
- Reporting date
- 24 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 24 Oct 2025
- Reporting date
- 24 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 23 Oct 2025
- Reporting date
- 23 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI
- Filing date
- 22 Oct 2025
- Reporting date
- 22 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 22 Oct 2025
- Reporting date
- 22 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
LATOZINEMAB DATA READ OUT
- Filing date
- 22 Oct 2025
- Reporting date
- 22 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS
- Filing date
- 21 Oct 2025
- Reporting date
- 21 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 21 Oct 2025
- Reporting date
- 21 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR
- Filing date
- 21 Oct 2025
- Reporting date
- 21 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 20 Oct 2025
- Reporting date
- 20 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 17 Oct 2025
- Reporting date
- 17 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 16 Oct 2025
- Reporting date
- 16 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 16 Oct 2025
- Reporting date
- 16 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 Oct 2025
- Reporting date
- 15 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 15 Oct 2025
- Reporting date
- 15 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA
- Filing date
- 14 Oct 2025
- Reporting date
- 14 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 14 Oct 2025
- Reporting date
- 14 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 14 Oct 2025
- Reporting date
- 14 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 14 Oct 2025
- Reporting date
- 14 Oct 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing